Zentalis reports preclinical data linking Cyclin E1 to azenosertib sensitivity; expects clinical data in H1 2023

Zentalis Pharmaceuticals, Inc.

Preclinical data show azenosertib kills Cyclin E1-high tumor cells in vitro and inhibits patient-derived in vivo models.
Data presented at AACR 2023 suggest CCNE1 amplification/Cyclin E1 expression as potential predictive marker for patient enrichment.
Company now expects to share Phase 1b ovarian chemo combination clinical data in H1 2023, ahead of original guidance.
Collaboration with Dr. Gordon Mills of Oregon Health & Science University on Wee1 inhibition studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.